Previous study indicated a significant correlation between the tumor infiltrated (TI) ‐ NK cells and the response rate of neoadjuvant‐targeted therapy combined with chemotherapy in HER2+ BC patients,23 while our study found that peripheral NK cells distribution was a negative independent predictor(P = 0.03) of NAT efficacy in all BC patients, independent of molecular subtypes. The gene discussed is BRD2; the disease is breast cancer.